Recent Updates
Recently added Catalysts

Upcoming Catalyst

Drug Pipeline Intelligence

Clinical Trial Results

Inside Trades

Options Data

News Section

Hedge Funds

Ownership Trends

Competitive Position

Catalyst Pharmaceuticals, Inc.

$31.49

0 (0%)

C 50Pipeline Score Fair Value Pharma · Commercial
Market Cap
3.83 B
EPS
1.81
P/E Ratio
17.97 $
Value Trade
54.43 M
SEC Financials
Q1 2026

  • Dilution Risk

    5%

  • Revenue

    149.39 M

  • R&D Expenses

    2.66 M

  • Operating CF

    59.59 M

  • Total Assets

    1.15 B

  • Total Liabilities

    134.91 M

  • Equity

    1.01 B

  • D/E Ratio

    12,345

0.29 %
Week
21.07 %
1 Month
28.11 %
3 Month
37.83 %
6 Month
453.76 %
5 Year
421 %
All Time
Cash Data
Profitable

  • Cash Position

    1.15 B

  • Monthly Burn

    -

  • Runway

    12,345 mo

  • Burn Trend

    Stable

  • SEC Filing

    May 11, 2026
Overview
Volume
15.45 M
52 Week Range
19.05 - 32.56
% held by Insiders
8.8 %
% held by Institutions
83.42 %
Enterprise Value
3.07 B
Total Shares
122.43 M
Short %
0.29 %
Float Shares
115.58 M
Company Description
HQ: 355 ALHAMBRA CIRCLE, CORAL GAB...
Employees:182
https://www.catalystpharma.com

locked

Upcoming Catalyst
Catalyst Drug/Treatment Stage Probability of Approval Description Drug Type Therapeutic Area Source
PDUFA 2026
Example Drug Treatment for example condition requiring FDA review
Phase 3
-%

FDA review of the new drug application for the treatment of example condition.

Read More
Small Molecule
Oncology
Example Drug Treatment for example condition requiring FDA review
Phase 3
-%

FDA review of the new drug application for the treatment of example condition.

Read More
Small Molecule
Oncology
Example Drug Treatment for example condition requiring FDA review
Phase 3
-%

FDA review of the new drug application for the treatment of example condition.

Read More
Small Molecule
Oncology
Unlock Upcoming Catalyst data

Catalyst Timeline

Dated clinical, regulatory & corporate events for Catalyst Pharmaceuticals, Inc.

987Total events
2Upcoming
267Tier-1 (high impact)
2010 – 2037Coverage

Upcoming catalysts 2

TBD
T1Patent Expiry
Subscribe to view catalyst details
AGAMREEApproved
TBD
T1Patent Expiry
Subscribe to view catalyst details
FIRDAPSEApproved

Event history 2

TBD
▲AcquiredCorporate
Subscribe to view catalyst details
TBD
▲Topline ReadoutAGAMREEApprovedClinical Data
Subscribe to view catalyst details
Unlock the full Catalyst Timeline
Past FDA Catalysts & PDUFA Decisions
Date Drug Catalyst Stage Outcome Reaction Event Move % Best Trade %
2024-06-04
Firdapse (amifampridine phosphate)
PDUFA Date
PDUFA
Approved
–
–
–
2024-06-04
Firdapse (amifampridine phosphate)
PDUFA Date
PDUFA
Approved
–
–
–
2024-06-04
Firdapse (amifampridine phosphate)
PDUFA Date
PDUFA
Approved
–
–
–
Unlock 8 more historical catalysts
Drug Pipeline Intelligence
C50
Pipeline Score
$1.7B
Pipeline Value
Fair Value
Valuation Signal
7
Drugs Scored
1.5x
rNPV / MCap
Top 79%
Small Cap
(rank 193 of 913)
Percentile Rank
Catalyst Pharmaceuticals, Inc. carries a moderate pipeline score (50/100), with $2.6B risk-adjusted pipeline value, led by amifampridine in Myasthenic Syndromes, Congenital (Phase 3), across $61B in total addressable markets.
Showing 1 of 1 assets
DrugIndicationPhaseNCT IDPTRSrNPVStatusEnrollmentVelocityDesignCompletionML SignalLast Change
amifampridine
Small molecule		Myasthenic Syndromes, CongenitalPhase 3NCT0256206644% $615M COMPLETED 20 - -Oct 1, 2019 -Apr 2, 2021
Unlock Drug Pipeline Intelligence
Clinical Trial Results
Drug Name Indications Phase Date Trial Results Summary Title Source
AGAMREE®
chronic inflammatory rare diseases
Phase 1
2026-07-01

AGAMREE® shows less pronounced immunosuppressive biomarker effects; Clinically relevant immunosuppressive effects were observed only at the highest dose level; No relevant immunosuppressive effects were observed at lower dose levels

Read More

Santhera Notes Topline Results from Catalyst Pharmaceuticals’ Phase 1 Clinical Study of AGAMREE®

Read More
AGAMREE®
chronic inflammatory rare diseases
Phase 1
2026-07-01

AGAMREE® shows less pronounced immunosuppressive biomarker effects; Clinically relevant immunosuppressive effects were observed only at the highest dose level; No relevant immunosuppressive effects were observed at lower dose levels

Read More

Santhera Notes Topline Results from Catalyst Pharmaceuticals’ Phase 1 Clinical Study of AGAMREE®

Read More
AGAMREE®
chronic inflammatory rare diseases
Phase 1
2026-07-01

AGAMREE® shows less pronounced immunosuppressive biomarker effects; Clinically relevant immunosuppressive effects were observed only at the highest dose level; No relevant immunosuppressive effects were observed at lower dose levels

Read More

Santhera Notes Topline Results from Catalyst Pharmaceuticals’ Phase 1 Clinical Study of AGAMREE®

Read More
Unlock Clinical Trial Results data
Inside Trades
TREND
CORPORATE INSIDERS BOUGHT SHARES WORTH 1.8M IN THE LAST 3 MONTHS
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Unlock Inside Trades data
Show Data
Hedge Funds
TREND
HEDGE FUNDS INCREASED HOLDINGS BY 200.0K SHARES IN THE LAST QUARTER
Shares Held
2040.00B1530.00B1020.00B510.00B0
Q3
2024
Q4
2024
Q1
2025
Q2
2025
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Fund Count
60%
Share Volume
25%
Conviction
15%
Hedge Funds invested in CPRX
HedgeFund Name
( 3 )
% of Portfolio Current MV
-
Shares Owned
-
Activity
Avg Price $0

Example Capital Management

2.5 %
15.00 M
250.00 K

Example Capital Management

2.5 %
15.00 M
250.00 K

Example Capital Management

2.5 %
15.00 M
250.00 K
Unlock Hedge Funds table data
CPRX Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
ExpirationVolumeOpen InterestImplied Volatility CallsImplied Volatility Puts
CallsPutsPut-Call RatioCallsPutsPut-Call RatioIVOiWaIvVWaIvIVOiWaIvVWaIv
2026-08-21 0.00 0 - - - - - -
2026-08-21 0.00 0 - - - - - -
2026-08-21 0.00 0 - - - - - -
Unlock Option Chain Statistics data
Option Chain
CallsStrikePuts
Last PriceVolumeOpen InterestLast PriceVolumeOpen Interest
No data available
Unlock Option Chain data
Unlock Options Chart data
Open interest
0 600K 1.2M 1.8M Avg OI 1.00 M Open Interest
0 1 2 3 1.1 Put-Call Ratio
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
0 450K 900K 1.4M Avg OV 750.00 K Option Volume
0 1 2 3 0.95 Put-Call Ratio
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
Competitive Position
How CPRX ranks across every disease it competes in
Competitive Position is a premium feature
See how CPRX ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial